Regulators align on Artificial Intelligence rules for drug development and medical devices
Regulators in the U.S., EU, and UK are building coordinated frameworks to govern the use of Artificial Intelligence across the drug and medical device lifecycle, seeking to balance rapid innovation with patient safety, transparency, and trust.